NVCR — Novocure Ltd stock price, charts and financials

NASDAQ·Healthcare·Medical - Devices·Switzerland

Latest market price

16.27

+0.95+6.20%

Overview Short InterestFilings

NVCRQT62Novocure Ltd·NASDAQ

Overview Short InterestFilings

16.27+6.20%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

INSP+22.83%$64.14 ENOV-1.78%$30.86 ATEC+1.97%$10.35 BFLY+7.18%$8.81 CNMD-2.82%$50.40 AXGN+0.50%$45.96 IART+0.11%$17.90 TNDM+0.45%$20.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-1.30	Insider Own	3.62%	Shs Outstand	115.82M	Perf Week	-0.25%

Market Cap	1.88B	Forward P/E	-	EPS next Y	-0.82	Insider Trans	-5.38%	Shs Float	95.84M	Perf Month	-6.06%

Enterprise Value	1.68B	PEG	-	EPS next Q	-0.23	Inst Own	-	Short Float	11.96%	Perf Quarter	-3.90%

Income	-148.00M	P/S	2.70	EPS this Y	3.79%	Inst Trans	-	Short Ratio	6.66	Perf Half Y	33.47%

Sales	699.00M	P/B	5.58	EPS next Y	34.73%	ROA	-18.68%	Short Interest	11.46M	Perf YTD	25.83%

Book/sh	2.92	P/C	4.27	EPS next 5Y	-	ROE	-44.00%	52W High	21.45 -24.15%	Perf Year	43.73%

Cash/sh	3.81	P/FCF	-	EPS past 3/5Y	-	ROIC	-26.15%	52W Low	9.82 65.68%	Perf 3Y	-51.17%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	6.78% 5.80%	Gross Margin	76.13%	Volatility	5.64% 6.41%	Perf 5Y	-90.98%

Dividend TTM	-	EV/Sales	2.40	EPS Y/Y TTM	16.67%	Oper. Margin	-22.08%	ATR (14)	1.19	Perf 10Y	40.50%

Dividend Ex-Date	-	Quick Ratio	2.70	Sales Y/Y TTM	15.54%	Profit Margin	-21.25%	RSI (14)	50.36	Recom	2.47

Dividend Gr. 3/5Y	-	Current Ratio	2.89	EPS Q/Q	63.89%	SMA20	-0.28%	Beta	1.03	Target Price	26.00

Payout	0.00%	Debt/Eq	0.86	Sales Q/Q	15.72%	SMA50	-1.10%	Rel Volume	1.00	Prev Close	15.32

Employees	1,605	LT Debt/Eq	0.82	Earnings	Oct 29	SMA200	17.82%	Avg Volume	1.73M	Price	16.27

IPO Date	Oct 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	60.79% 6.46%	Net Debt/EBITDA	-1.04	Volume	1,739,931	Change	6.20%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-24-26	Reiterated	Wedbush	Neutral	$20
Jul-23-26	Reiterated	H.C. Wainwright	Buy	$46 → $52
Jun-18-26	Reiterated	HC Wainwright & Co.	Buy	$47 → $46
Feb-12-26	Reiterated	HC Wainwright & Co.	Buy	$39 → $47
Jan-13-26	Reiterated	HC Wainwright & Co.	Buy	$42 → $39
Jan-05-26	Reiterated	Evercore ISI	Outperform	$22 → $20
Oct-30-25	Reiterated	HC Wainwright & Co.	Buy	$30 → $42
Jul-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$15
Dec-02-24	Upgrade	Evercore ISI Group	In Line → Outperform	$15 → $30
Oct-16-24	Upgrade	HC Wainwright & Co.	Neutral → Buy	$24 → $30

Latest News

Jul-27-26

Jul-27-2601:01PM

NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?zacks.com

11:03AM

Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Tradezacks.com

10:29AM

Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospectszacks.com

Jul-24-26

Jul-24-2601:45PM

NovoCure: Why I'm Fading The Q2 Earnings Rallyseekingalpha.com

10:21AM

NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)seekingalpha.com

Jul-23-26

Jul-23-2602:30PM

The market is filled with gapping stocks in Thursday's session.ChartMill

01:00PM

NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcriptseekingalpha.com

09:16AM

NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimateszacks.com

09:08AM

NovoCure Q2 Earnings Call Highlightsmarketbeat.com

08:00AM

Novocure Reports Second Quarter 2026 Financial Resultsgurufocus.com

Jul-16-26

Jul-16-2611:06AM

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Releasezacks.com

10:00AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCRprnewswire.com

Jul-14-26

Jul-14-2606:24PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCRglobenewswire.com

Jul-13-26

Jul-13-2607:09AM

JP Morgan Reinstates Neutral on NovoCure, Announces $17 Price TargetBenzinga

Jul-10-26

Jul-10-2603:01PM

NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026seekingalpha.com

Company

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	699	655	605	509	538	535	494	351	248
Cost of Goods Sold Incl. D&A	167	167	137	128	115	115	107	89	80
Gross Profit	531	488	468	381	423	420	388	263	168
Selling, General and Administrative Excl. Other	462	418	429	391	306	263	225	185	151
Research and Development	224	225	210	223	206	201	132	79	51
Other Operating Expense	1	-1	0	1	0	0	0	0	0
Operating Income	-154	-154	-170	-233	-90	-44	30	-1	-34
Interest Expense	3	0	12	5	8	9	18	15	17
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	4	18	51	46	16	1	6	7	5
Net Income Before Taxes	-152	-136	-131	-192	-82	-52	18	-9	-46
Income Taxes	-4	0	37	15	11	6	-2	-2	18
Consolidated Net Income	-148	-136	-169	-207	-93	-58	20	-7	-64
Net Income From Continuing Operations	-148	-136	-169	-207	-93	-58	20	-7	-64
Net Income	-148	-136	-169	-207	-93	-58	20	-7	-64
EPS (Recurring)	-1.30	-1.22	-1.56	-1.95	-0.88	-0.56	0.20	-0.07	-0.69
EPS (Basic, Before Extraordinaries)	-1.30	-1.22	-1.56	-1.95	-0.88	-0.56	0.20	-0.07	-0.69
EPS (Diluted)	-1.30	-1.22	-1.56	-1.95	-0.88	-0.56	0.18	-0.07	-0.69
EBITDA	-134	-119	-110	-177	-68	-38	45	13	-23
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	961.33	—	—
Price To Sales Ratio	2.70	2.19	5.32	3.11	14.32	14.45	35.38	23.29	12.42
Gross Margin	75.97	74.50	77.36	74.85	78.62	78.50	78.54	74.93	67.74
Operating Margin	-22.03	-23.51	-28.10	-45.78	-16.73	-8.22	6.07	-0.28	-13.71
Net Margin	-21.17	-20.76	-27.93	-40.67	-17.29	-10.84	4.05	-1.99	-25.81
Shares Outstanding	116	111	108	106	105	103	101	97	92
Market Capitalization	1,887	1,435	3,218	1,583	7,702	7,733	17,477	8,174	3,080
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leonard Frank X	Chief Executive Officer	Jun 04 '26	Sale	17.93	34,273	614,635	459,520	Jun 05
Stafford Kristin	Director	Jun 02 '26	Sale	15.77	2,945	46,445	11,324	Jun 03
Scannell Timothy J	Director	Jun 02 '26	Sale	15.77	2,945	46,445	14,288	Jun 03
LEUNG GABRIEL	Director	Jun 02 '26	Sale	15.77	2,945	46,445	89,499	Jun 03
Ocean Allyson J	Director	Jun 02 '26	Sale	15.77	2,945	46,445	11,324	Jun 03
HILLEMAN JERYL L	Director	Jun 02 '26	Sale	15.77	2,945	46,445	13,861	Jun 03
VERNON W ANTHONY	Director	Jun 02 '26	Sale	15.77	2,945	46,445	197,657	Jun 03
Hung David	Director	Jun 02 '26	Sale	15.77	2,945	46,445	20,465	Jun 03
VERNON W ANTHONY	Director	Apr 28 '26	Option Exercise	11.39	21,500	244,885	200,602	Apr 28
Paravasthu Mukund	Chief Operating Officer	Mar 05 '26	Sale	13.77	43,246	595,670	72,832	Mar 05
Brackmann Christoph	Chief Financial Officer	Mar 04 '26	Sale	13.31	6,412	85,314	182,842	Mar 05
Leupin Nicolas	Former Chief Medical Officer	Mar 04 '26	Sale	13.31	1,100	14,636	102,979	Mar 05
Puri Michal Nath	Chief Human Resources Officer	Mar 04 '26	Sale	13.31	1,100	14,636	201,322	Mar 05
Paravasthu Mukund	Chief Operating Officer	Mar 04 '26	Sale	13.31	5,377	71,543	116,078	Mar 05
Weinberg Uri	Chf Medical and Innovation Ofr	Mar 04 '26	Sale	13.31	6,412	85,314	267,190	Mar 05

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.